Roche bets on obesity trump card

Roche has shored up its obesity portfolio by partnering with Zealand Pharma for a much-hyped amylin analog in Phase 2 trials in a deal worth up to AU$8.3 billion.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here